Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer-Reference-Cited by-同舟云学术

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Published:2012-01-26 Issue:4 Volume:366 Page:299-309
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

von Minckwitz Gunter,Eidtmann Holger,Rezai Mahdi,Fasching Peter A.,Tesch Hans,Eggemann Holm,Schrader Iris,Kittel Kornelia,Hanusch Claus,Kreienberg Rolf,Solbach Christine,Gerber Bernd,Jackisch Christian,Kunz Georg,Blohmer Jens-Uwe,Huober Jens,Hauschild Maik,Fehm Tanja,Müller Berit Maria,Denkert Carsten,Loibl Sibylle,Nekljudova Valentina,Untch Michael

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111065

Cited by 457 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, her2-negative breast cancer: a network meta-analysis;Frontiers in Immunology;2024-08-23

2. Electroacupuncture facilitates vascular normalization by inhibiting Glyoxalase1 in endothelial cells to attenuate glycolysis and angiogenesis in triple-negative breast cancer;Cancer Letters;2024-08

3. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis;Expert Review of Anticancer Therapy;2024-05-17

4. Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment;PLOS Computational Biology;2024-05-03

5. A mathematical model for the role of dopamine-D2 self-regulation in the production of ultradian rhythms;PLOS Computational Biology;2024-05-03